Merck & Co., Inc. (MRK)

Merck will lay off about 150 employees across its facility in North Carolina that manufactures its human papillomavirus vaccine, Gardasil, according to a notice filed in the state's database this week.

Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer rega.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will.

Choreo LLC trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 4.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,377 shares of the company's stock after selling 5,332 shares during the quarter. Choreo LLC's holdings in

DNB Asset Management AS lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 748,427 shares of the company's stock after selling 5,667 shares during the period. DNB Asset

Guru Stock PicksMS Global Franchise Portfolio has made the following transactions:Reduce in MSCI by 17.11%Sold out in FDSAdd in LSE: EXPN by 13.74%New position i

A giant in the healthcare space, Merck ( NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week.

Shifting from higher-risk assets to consistent income sources is a natural progression for retirees.

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). STK-012, a first-in-class α/β-IL-2 receptor biased partial agonist, will be evaluated in combination with standard of care chemotherapy and Keytruda® (pembrolizumab), Merck's anti-PD-1 (programmed cell death receptor-1) therapy, in the ongo.

Stock News Nvidia posts record quarter, upbeat outlook: Nvidia (NVDA) reported Q4 revenue of $68.13B with data center sales at $62.3B (91% of total) and guided

Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.

Exploring the Fourth Quarter 2025 N-PORT Filing Bill Nygren (Trades, Portfolio) recently submitted the N-PORT filing for the fourth quarter of 2025, providing

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to b.

Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026.